Imagine a weight loss shot you only take once a month that works better than some of today’s top drugs. That’s the promise of MariTide, a new injection that’s turning heads after its first trial outperformed Wegovy and Mounjaro. These drugs, originally for diabetes, are now widely used for weight loss, helping people with obesity or heart risks slim down. But MariTide’s fresh approach is stealing the spotlight.
What makes MariTide special is its once-a-month dosing, unlike the weekly shots required by Wegovy and Mounjaro. A unique ingredient, a monoclonal antibody, keeps the drug working longer in the body. Dr. Michelle Ponder from Duke University said this is a big deal for patients, especially those with diabetes who already juggle multiple daily shots. Fewer injections mean less hassle and a better chance of sticking with the plan.
The trial tested MariTide on 600 people, split into groups with obesity alone or with obesity and Type 2 diabetes. They got one of three MariTide doses or a placebo, taken monthly for a year. The results were jaw-dropping: those with obesity alone shed up to 20% of their body weight, while the placebo group lost just 2.6%.
For those with diabetes, MariTide led to a 17% weight loss, compared to a mere 1.4% for the placebo group. Jay Bradner, a key researcher at Amgen, called the findings a breakthrough, noting steady weight loss, better heart health, and the potential for monthly dosing to keep patients motivated. These results are paving the way for larger studies to confirm MariTide’s promise.
This new shot could be a game-changer for anyone looking to lose weight and feel healthier. With its easy schedule and impressive results, MariTide offers a fresh way to tackle weight loss challenges. Keep an eye on this one—it might just redefine how we approach fitness and wellness in the years to come.